Oncology Institute Inc 最近的每股收益为 $-0.06,未达预期 $-0.09 的预期。
Oncology Institute Inc TOI 上一季度的收入表现如何?
Oncology Institute Inc 上一季度的收入为 $-0.06
Oncology Institute Inc 的收入预期是多少?
根据 5 位华尔街分析师的预测,Oncology Institute Inc 的收入预期范围从 $166.43M 到 $150.22M
Oncology Institute Inc 的盈利质量评分是多少?
Oncology Institute Inc 的盈利质量评分为 B+/56.547325。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Oncology Institute Inc 何时发布财报?
Oncology Institute Inc 的下一份财报预计在 2026-06-10 发布
Oncology Institute Inc 的预期收益是多少?
根据华尔街分析师的预测,Oncology Institute Inc 的预期收益为 $141.17M
Oncology Institute Inc 是否超出收益预期?
Oncology Institute Inc 最近的收益为 $141.95M,超出预期 预期。
关键数据
前收盘价
$2.83
开盘价
$2.87
当日区间
$2.87 - $3.1
52周范围
$1.03 - $4.88
交易量
1.6M
平均成交量
2.1M
股息收益率
--
每股收益(TTM)
-0.68
市值
$301.4M
什么是 TOI?
The Oncology Institute, Inc. provides cancer care treatment services. The company is headquartered in Cerritos, California and currently employs 641 full-time employees. The company went IPO on 2020-03-13. The firm manages community-based oncology practices which serve patients at approximately 86 clinic locations across 16 markets and five states throughout the United States. The firm's segment includes patient services, dispensary, and clinical trials & other. Its managed clinics provide a range of medical oncology services, including physician services, in-house infusion, radiation, and programs like outpatient blood product transfusions, along with 24/7 patient support. The Company, through TOI Clinical Research, LLC (TCR), provides and manages clinical trial services and research for the benefit of cancer patients. The firm also provides management services to over 14 clinic locations owned by independent oncology practices. The firm and its affiliated providers have contractual relationships with payors serving a variety of patients, including Medicare Advantage (MA), Medicaid, and commercial patients.